Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
Companies Commented On
- Concert Pharmaceuticals
- CTI BioPharma
- Nektar Therapeutics
- Targacept Inc.
Robert (Bert) Hazlett, a biopharmaceuticals senior research analyst, joined ROTH Capital Partners in 2012. Hazlett has more than 15 years of equity research experience covering the biopharmaceuticals sector. Prior to joining ROTH, Hazlett was a managing director and senior analyst at BMO Capital Markets, covering both the large capitalization and emerging pharmaceuticals sectors. Before BMO, he covered similar sectors as a managing director at SunTrust Robinson Humphrey, as a vice president at Robertson Stephens, and also held analyst positions in healthcare research at Lehman Brothers and UBS Securities. Hazlett received his master's degree in business administration (finance) in 1996 from Columbia University and a bachelor's degree in economics in 1987 from Yale University.
Meet High Risk and High Reward, Biotech's Profit Partners: Bert Hazlett (7/25/13) Small-cap biotech investing carries real risk. Startup companies tend to have only a few ideas in development, which leaves ample room for setbacks—even room for disaster. Robert "Bert" Hazlett, senior biotechnology research analyst with ROTH Capital Partners, doesn't mind taking such risks, but tempers them with a diversification strategy designed to minimize the impact of potential hiccups and blowups. In this interview with The Life Sciences Report, Hazlett expands on his strategy and mentions four companies with experienced management teams and high hopes for huge returns.
"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >
"We are very excited about RNN; it's an early-stage oncology company with multiple shots on goal." (7/31/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Christopher James More >